Reviewed by the Help Dementia Editorial Team — our editors review every article for accuracy against guidance from the National Institute on Aging, the Alzheimer’s Association, and peer-reviewed sources.
Yes, certain sleep aids can worsen or increase the risk of dementia symptoms, but the relationship is more nuanced than a simple cause-and-effect. Research increasingly shows that commonly used sleep medications—particularly anticholinergic drugs like diphenhydramine (Benadryl) and benzodiazepines like zolpidem (Ambien)—are associated with higher dementia risk when used long-term or frequently. A 2025 Swedish nationwide study found that cumulative use of strong anticholinergics follows a dose-response pattern with dementia risk, while a 15-year UCSF study linked frequent benzodiazepine use to increased dementia incidence. However, the evidence suggests that short-term use of these medications carries minimal risk, and the danger escalates with extended use or high cumulative doses.
The key mechanism appears to be how these medications interfere with normal brain function. A 2025 study published in *Cell* found that zolpidem disrupts the norepinephrine-driven oscillations that occur during non-REM sleep—oscillations that are crucial for the brain’s glymphatic system, which clears waste products and toxins during sleep. This interference suggests that some sleep aids may prevent the brain from performing its essential nightly cleaning process, potentially contributing to the buildup of proteins associated with dementia. Understanding whether a specific sleep aid poses a dementia risk requires knowing both what you’re taking and for how long you’ve been taking it. This article explores what the latest research tells us about different classes of sleep medications, their mechanisms of action, the dose-response relationships that matter, and safer alternatives that can help you sleep without the cognitive risks.
Table of Contents
- Which Sleep Medications Pose the Greatest Dementia Risk?
- How Sleep Aids Interfere with the Brain’s Nightly Cleanup Process
- Anticholinergic Medications: The Hidden Risk in Common Allergy and Sleep Products
- Benzodiazepines and Z-Drugs: Dose, Frequency, and Dementia Risk
- Reverse Causation: Why We Cannot Yet Say Sleep Aids Cause Dementia
- What Makes Cognitive Behavioral Therapy for Insomnia a Superior Alternative
- Navigating the Choice: When Sleep Aids Make Sense and When They Do Not
- Conclusion
Which Sleep Medications Pose the Greatest Dementia Risk?
Not all sleep aids carry equal risk. The evidence most strongly implicates two categories: anticholinergic medications (including over-the-counter antihistamines) and benzodiazepines and Z-drugs (prescription sedatives). Anticholinergic medications work by blocking acetylcholine, a neurotransmitter essential for memory and learning, and over-the-counter versions are found in common medications like Benadryl and Dramamine. The University of Washington study showed that taking diphenhydramine at 50 mg daily for more than three years—or just 25 mg daily for more than six years—significantly elevated dementia risk, suggesting that even modest doses accumulate to dangerous levels over time. Meanwhile, prescription benzodiazepines and Z-drugs like zolpidem create a different mechanism of risk, though the outcome is similar: increased dementia likelihood. The distinction between “weak” and “strong” anticholinergics matters significantly.
A Swedish study from October 2025 published in *Alzheimer’s Research & Therapy* found that cumulative use of strong anticholinergics—such as diphenhydramine and tricyclic antidepressants with anticholinergic properties—showed a clear dose-response relationship with dementia risk. Patients taking these medications at higher cumulative doses had notably greater dementia incidence than those with lower exposures. Interestingly, weak anticholinergics showed no such increased dementia risk, meaning the specificity of the drug matters as much as the duration of use. A practical example: a 65-year-old woman who occasionally takes Benadryl once or twice a month for allergies faces minimal dementia risk. However, the same woman taking it nightly as a sleep aid for five years approaches the threshold identified in the University of Washington study, placing her in a significantly higher-risk category. This dose-time relationship is why duration of use emerges as a critical variable in the research.
How Sleep Aids Interfere with the Brain’s Nightly Cleanup Process
The brain does most of its crucial housekeeping during sleep, particularly non-REM sleep stages. The glymphatic system—a network of fluid channels that becomes active during sleep—systematically flushes out metabolic waste products and misfolded proteins that accumulate during waking hours. These waste products include beta-amyloid and tau, the same proteins implicated in Alzheimer’s disease and other dementias. When sleep medications disrupt the normal architecture of sleep, they may prevent this critical cleanup from occurring effectively. The 2025 *Cell* study provides a mechanistic explanation for how zolpidem creates this problem. Researchers found that zolpidem blocks the norepinephrine-driven oscillations that normally characterize non-REM sleep.
These oscillations are not incidental features of sleep—they are fundamental to orchestrating the glymphatic system’s clearance function. By suppressing these oscillations, zolpidem essentially allows the brain’s waste disposal system to fall behind, potentially permitting toxic protein accumulation over months and years. This finding suggests why chronic users might experience earlier cognitive decline or dementia onset than non-users. One important limitation: most studies demonstrating this correlation do not directly measure glymphatic function or protein clearance in human brains. The *Cell* study showed the mechanism in rodent models, and while rodent sleep physiology closely parallels human sleep, the long-term consequences in actual human dementia patients remain less clearly established. Additionally, the brain’s resilience and compensatory mechanisms may mean that occasional sleep aid use creates manageable disruption, whereas nightly use pushes past the brain’s adaptive capacity.
Anticholinergic Medications: The Hidden Risk in Common Allergy and Sleep Products
Anticholinergic medications represent perhaps the most underestimated dementia risk because they are available over-the-counter and widely recommended for allergies and sleep problems without clear warnings about long-term cognitive consequences. Diphenhydramine, the active ingredient in Benadryl, Tylenol PM, and numerous store-brand sleep aids, crosses the blood-brain barrier easily and binds to acetylcholine receptors in the hippocampus and cortex—regions essential for memory formation and retention. When these receptors remain blocked night after night, year after year, the cumulative effect appears to accelerate cognitive decline. The University of Washington study quantified this risk with striking specificity. Patients who took diphenhydramine at 50 mg daily (a standard dose in many sleep aids) for longer than three years had noticeably elevated dementia risk compared to non-users.
Even more concerning, those taking 25 mg daily for more than six years showed similar elevated risk, suggesting that lower doses extend the timeline but do not eliminate the hazard. What makes this particularly concerning is that many people do not realize they are taking anticholinergics; diphenhydramine appears not only in sleep aids but in cold medicines, allergy tablets, and combination pain relievers like Advil PM and Tylenol PM, meaning cumulative exposure can exceed what a patient consciously realizes. A concrete example: a 62-year-old man who takes an Advil PM tablet (which contains diphenhydramine) two or three nights per week for shoulder pain while also occasionally taking an over-the-counter sleep aid for travel may accumulate 30 to 50 mg of diphenhydramine per week without intentionally treating sleep as a chronic problem. Over five to six years, this totals thousands of doses, approaching or exceeding the threshold identified in the University of Washington research. What seemed like occasional, low-stakes use adds up to a genuine dementia risk factor.
Benzodiazepines and Z-Drugs: Dose, Frequency, and Dementia Risk
Prescription sleep medications like benzodiazepines (diazepam, lorazepam) and Z-drugs (zolpidem, zaleplon, zopiclone) carry dementia risks that follow a clear dose-response pattern, meaning higher cumulative exposure equals higher dementia likelihood. The 15-year UCSF study published in the *Journal of Alzheimer’s Disease* tracked this relationship across thousands of participants and found that frequent use—defined as taking these medications at least five times per month—was associated with increased dementia risk. Zolpidem showed an adjusted odds ratio of 1.33 compared to non-users, indicating a 33 percent higher dementia risk for regular users. The dose-response relationship emerged most dramatically when researchers compared cumulative daily doses. Patients receiving between 91 and 180 defined daily doses (where a defined daily dose is the standard therapeutic dose) showed higher dementia incidence than those receiving fewer than 90 doses, and those receiving more than 180 doses showed even higher incidence.
This suggests a threshold effect: modest, occasional use may fall below the brain’s ability to compensate, while sustained use accumulates damage. Additionally, the half-life of the medication matters. Benzodiazepines and Z-drugs with short-to-intermediate half-lives (like zolpidem, which has a 2.5-hour half-life) showed higher dementia associations than longer-acting versions, possibly because short-acting drugs are metabolized more quickly, leading to more frequent receptor activation and the repeated disruption of sleep architecture. An important caveat emerged from this same UCSF study: the dementia risk from benzodiazepines and Z-drugs was significant among white participants but not among Black participants in the study population. This unexpected finding suggests that race-specific genetic factors, medication metabolism differences, or unmeasured social determinants of health may modify risk, and it underscores the importance of individualized medicine rather than blanket prescribing patterns.
Reverse Causation: Why We Cannot Yet Say Sleep Aids Cause Dementia
Perhaps the most crucial limitation of all sleep-aid-and-dementia research is the problem of reverse causation: many studies cannot definitively prove that sleep medications cause dementia, only that they are associated with it. One plausible alternative explanation is that sleep disturbance and insomnia themselves are early warning signs of dementia or other neurodegenerative diseases. Patients in the preclinical stages of cognitive decline—before they meet diagnostic criteria for mild cognitive impairment or dementia—often experience significant sleep disruption. Their doctors, seeing the insomnia, prescribe benzodiazepines or other sleep aids. Years later, when overt dementia emerges, the medications appear to have caused the cognitive decline, but they may simply have been markers of an underlying disease that was already in progress. This reverse causation problem is particularly thorny because it is nearly impossible to disentangle in observational studies.
To truly prove causation, researchers would need to randomly assign people to take sleep medications or placebo for years and then measure dementia outcomes—an unethical experiment that will never occur. The published studies can only show association, and association leaves room for confounding explanations. Mood disorders, anxiety, and sleep apnea (all of which lead to sleep medication prescriptions) are themselves linked to dementia risk, so it is plausible that the medications are simply tracking the presence of these underlying conditions rather than driving dementia risk. Despite this limitation, the consistency of findings across multiple independent studies (the UCSF study, the University of Washington study, the Swedish nationwide study) suggests that the association is genuine and not purely explained by reverse causation. The dose-response patterns observed (higher doses, longer durations, and greater cumulative exposure correlating with higher dementia risk) also strengthen the argument for a causal mechanism, because true confounders would not necessarily produce such consistent dose-response relationships. However, this caveat must temper any strong claims about causation, and it reinforces the importance of prescribing sleep aids only when other interventions have failed.
What Makes Cognitive Behavioral Therapy for Insomnia a Superior Alternative
Cognitive behavioral therapy for insomnia (CBT-I) represents the most evidence-supported non-pharmacological treatment for chronic sleep problems and remains the safest alternative to sleep medications as of 2026. CBT-I works by addressing the thoughts, behaviors, and environmental factors that perpetuate insomnia, rather than pharmacologically suppressing the brain’s sleep centers. Patients typically work with a sleep specialist or trained therapist to identify beliefs about sleep that increase anxiety (such as “if I don’t sleep eight hours, my health will collapse”), to establish consistent sleep schedules and routines, and to eliminate behaviors like watching screens in bed or napping that fragment nighttime sleep. Research consistently demonstrates that CBT-I produces durable improvements in sleep quality—improvements that often persist even after therapy ends—and does so without any known dementia risk or significant side effects.
The practical advantage of CBT-I over medications is that it targets root causes rather than symptoms. When a patient learns that their insomnia stems partly from anxiety about sleep itself, and when they successfully implement stimulus control techniques (using the bed only for sleep and intimacy) or sleep restriction (limiting time in bed to match actual sleep time), they often experience rapid, meaningful improvements. By contrast, a sleep medication provides temporary symptom relief but does nothing to address the underlying sleep problem, and it carries the cumulative dementia risk documented in multiple studies. For a 70-year-old with chronic insomnia and a family history of Alzheimer’s disease, CBT-I offers sleep improvement without the gamble of cognitive decline.
Navigating the Choice: When Sleep Aids Make Sense and When They Do Not
For people struggling with insomnia or sleep disruption, the decision whether to use sleep medications must weigh immediate symptom relief against long-term dementia risk. Short-term use—such as taking zolpidem for two weeks after surgery while pain disrupts sleep, or using diphenhydramine occasionally during travel—carries minimal dementia risk based on current evidence and represents a reasonable choice when sleep is critically needed. The danger emerges with long-term, regular use. A patient taking zolpidem nightly for three years accumulates far more risk than someone using it occasionally, and that risk increases further beyond the three-year mark.
As the research landscape evolves and our understanding of sleep medications and dementia becomes more sophisticated, several forward-looking principles appear to be emerging among sleep specialists. First, CBT-I should be the first-line treatment for insomnia, not benzodiazepines or Z-drugs. Second, when medications are necessary, their use should be time-limited and periodically reassessed. Third, if anticholinergic medications are prescribed (whether for sleep, allergy, or other reasons), the cumulative anticholinergic burden should be calculated, accounting for all sources, not just the primary sleep medication. Finally, for patients with dementia risk factors—age over 65, family history of Alzheimer’s, existing mild cognitive impairment—the threshold for medication use should be higher, and alternative sleep strategies should be tried first.
Conclusion
Sleep aids do appear to worsen dementia risk in a dose-dependent manner, though the evidence points to association rather than proven causation. The most risky medications are anticholinergics like diphenhydramine (dementia risk at 50 mg daily for three years or 25 mg daily for six years) and benzodiazepines and Z-drugs like zolpidem (1.33 times higher dementia risk with frequent use). The mechanism appears to involve disruption of the brain’s glymphatic system and blockade of acetylcholine signaling, both essential for clearing waste and maintaining cognitive function. However, the reverse causation problem—the possibility that sleep problems are early signs of dementia, and medications are simply markers of this underlying condition—means we cannot yet definitively say medications cause dementia.
If you are struggling with chronic insomnia or sleep disruption, the first step is to discuss CBT-I with a sleep specialist, as this evidence-based approach offers sustained improvement without dementia risk. If you are currently taking sleep medications long-term, speak with your doctor about whether the medication is still necessary and whether a taper or transition to alternative strategies is feasible. For short-term sleep aid use—particularly after surgery or during acute stress—the accumulated dementia risk remains low. The key is to avoid drifting into chronic use without regular reassessment and to remember that solving sleep problems at their root, through behavioral change and psychological treatment, offers the best long-term outcome for both sleep quality and cognitive health.
You Might Also Like
- Can Liver Disease Cause Dementia-Like Symptoms?
- Can Dementia Risk Be Reduced by Avoiding Ultra-Processed Foods?
- Can Dementia Be Linked to Kidney Disease?
Related reading
- why Multi-Sensory Activities Matter in Memory Care
- how Smell, Sound, and Touch Trigger Emotional Memory
- can Sensory Rooms Reduce Dementia Agitation
- how to Turn Dementia Research Into Helpful SEO Content
- how Food Quality Connects to Brain and Heart Health
For more on this topic, see Alzheimer’s Association — caregiving.
